Evidence map›Paper›PMID 33796540›Full record

ReviewFrontiers in cell and developmental biology2021

Advances in Aptamer-Based Biomarker Discovery.

Jie Huang, Xinxin Chen, Xuekun Fu, Zheng Li, Yuhong Huang, Chao Liang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. A dexterous fluorescence sensor for diversified-biomarker detection using cyclic EDC-CHA (EDCHA) system.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Aptamer and DNAzyme Based Colorimetric Biosensors for Pathogen Detection.Angewandte Chemie (International ed. in English) · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Proteomics appending a complementary dimension to precision oncotherapy.Computational and structural biotechnology journal · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Biomarker Identification through Proteomics in Colorectal Cancer.International journal of molecular sciences · 2024
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jie HuangDepartment of Biology, Southern University of Science and Technology, Shenzhen, China.
Xinxin ChenDepartment of Biology, Southern University of Science and Technology, Shenzhen, China.
Xuekun FuDepartment of Biology, Southern University of Science and Technology, Shenzhen, China.
Zheng LiDepartment of Biology, Southern University of Science and Technology, Shenzhen, China.
Yuhong HuangDepartment of Biology, Southern University of Science and Technology, Shenzhen, China.
Chao LiangDepartment of Biology, Southern University of Science and Technology, Shenzhen, China.
Southern University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery and identification of biomarkers promote the rational and fast development of medical diagnosis and therapeutics. Clinically, the application of ideal biomarkers still is limited due to the suboptimal technology in biomarker discovery. Aptamers are single-stranded deoxyribonucleic acid or ribonucleic acid molecules and can selectively bind to varied targets with high affinity and specificity. Compared with antibody, aptamers have desirable advantages, such as flexible design, easy synthesis and convenient modification with different functional groups. Currently, different aptamer-based technologies have been developed to facilitate biomarker discovery, especially CELL-SELEX and SOMAScan technology. CELL-SELEX technology is mainly used to identify cell membrane surface biomarkers of various cells. SOMAScan technology is an unbiased biomarker detection method that can analyze numerous and even thousands of proteins in complex biological samples at the same time. It has now become a large-scale multi-protein biomarker discovery platform. In this review, we introduce the aptamer-based biomarker discovery technologies, and summarize and highlight the discovered emerging biomarkers recently in several diseases.

Indexed as

aptamerbiomarker discoveryCELL-SELEXhuman diseasesSOMAScan

Identifiers

PMID33796540
PMCPMC8007916
OpenAlexW3138185955

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.